CDX-110
Phase 2b/3- Indications
- Glioblastoma multiforme
Company intelligence / Profile preview
Avant Immunotherapeutics, Inc.
Needham, Massachusetts, United Statesir.celldex.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Avant Immunotherapeutics developed a portfolio of therapeutic vaccines and immunotherapies targeting infectious diseases and cancers. Notable results included strong immunogenicity for its single-dose oral Ty800 typhoid vaccine (>90% immune response in Phase I/II) and advancement of CDX‑110 for glioblastoma into Phase II with Pfizer partnership. The company merged with Celldex Therapeutics in early/mid‑2008, after which it operated under the Celldex name.[4][6][8]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Therapeutic vaccinesMonoclonal antibodies (mAbs)Immunomodulators[4][8]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer – exclusive worldwide license for CDX‑110 therapeutic brain cancer vaccine candidate; also equity investment and milestone payments agreement[8]National Institute of Allergy and Infectious Diseases/National Institutes of Health – funding/support for Ty800 development/trials[6]Academic collaborations with Johns Hopkins University, Duke University Brain Tumor Center, MD Anderson Cancer Center on GBM program/CDX‑110 development[8]
Beyond the preview
Go deeper on Avant Immunotherapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avant Immunotherapeutics, Inc..